Refine
Has Fulltext
- yes (553)
Is part of the Bibliography
- yes (553) (remove)
Year of publication
- 2018 (553) (remove)
Document Type
- Journal article (364)
- Doctoral Thesis (156)
- Preprint (22)
- Conference Proceeding (3)
- Other (2)
- Working Paper (2)
- Book (1)
- Book article / Book chapter (1)
- Habilitation (1)
- Master Thesis (1)
Language
- English (553) (remove)
Keywords
- Parton Distributions (23)
- Hadron-Hadron scattering (experiments) (16)
- Positronen-Emissions-Tomografie (16)
- Extension (14)
- PET (14)
- Decay (13)
- boron (12)
- Squark (11)
- ++ (10)
- positron emission tomography (9)
Institute
- Physikalisches Institut (83)
- Theodor-Boveri-Institut für Biowissenschaften (81)
- Graduate School of Life Sciences (64)
- Klinik und Poliklinik für Nuklearmedizin (34)
- Institut für Anorganische Chemie (22)
- Institut für Psychologie (20)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (19)
- Medizinische Klinik und Poliklinik II (17)
- Institut für Informatik (15)
- Institut für Mathematik (14)
- Institut für Virologie und Immunbiologie (14)
- Medizinische Klinik und Poliklinik I (14)
- Institut für Pharmazie und Lebensmittelchemie (12)
- Rudolf-Virchow-Zentrum (12)
- Institut für Geographie und Geologie (11)
- Institut für Organische Chemie (11)
- Julius-von-Sachs-Institut für Biowissenschaften (11)
- Institut für Physikalische und Theoretische Chemie (10)
- Institut für Humangenetik (9)
- Institut für Sportwissenschaft (9)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (9)
- Institut für Anatomie und Zellbiologie (8)
- Institut für Molekulare Infektionsbiologie (8)
- Institut für Pharmakologie und Toxikologie (8)
- Kinderklinik und Poliklinik (8)
- Pathologisches Institut (8)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (7)
- Institut für Funktionsmaterialien und Biofabrikation (7)
- Institut für Theoretische Physik und Astrophysik (7)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (7)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (7)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (7)
- Neurologische Klinik und Poliklinik (7)
- Volkswirtschaftliches Institut (7)
- Graduate School of Science and Technology (6)
- Lehrstuhl für Orthopädie (6)
- Fakultät für Biologie (5)
- Institut für Hygiene und Mikrobiologie (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (5)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (5)
- Lehrstuhl für Molekulare Psychiatrie (5)
- Center for Computational and Theoretical Biology (4)
- Comprehensive Cancer Center Mainfranken (4)
- Medizinische Fakultät (4)
- Augenklinik und Poliklinik (3)
- Institut Mensch - Computer - Medien (3)
- Institut für Klinische Epidemiologie und Biometrie (3)
- Institut für Politikwissenschaft und Soziologie (3)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (3)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (3)
- Physiologisches Institut (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Betriebswirtschaftliches Institut (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Frauenklinik und Poliklinik (2)
- Institut für Experimentelle Biomedizin (2)
- Institut für Klinische Neurobiologie (2)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (2)
- Institut für Medizinische Strahlenkunde und Zellforschung (2)
- Klinik und Poliklinik für Strahlentherapie (2)
- Fakultät für Chemie und Pharmazie (1)
- Fakultät für Physik und Astronomie (1)
- Graduate School of the Humanities (1)
- Institut für Biblische Theologie (1)
- Institut für Evangelische Theologie und Religionspädagogik (1)
- Institut für Kulturwissenschaften Ost- und Südasiens (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (1)
- Philosophische Fakultät (Histor., philolog., Kultur- und geograph. Wissensch.) (1)
- Poliklinik für Kieferorthopädie (1)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (15)
- Johns Hopkins University School of Medicine (5)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- International Max Planck Research School Molecular Biology, University of Göttingen, Germany (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- ACC GmbH Analytical Clinical Concepts (1)
- BMBF (1)
- Boehringer Ingelheim Pharma GmbH & Co. KG (1)
ResearcherID
- J-8841-2015 (1)
Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phosphorylation in cancerous cell lines of different tissue origin. IL27 leads to STAT1 phosphorylation and recapitulates an IFN--like response in the microarray analyses, with up-regulation of genes involved in antiviral defense, antigen presentation, and immune suppression. Like IFN-, IL27 leads to an up-regulation of TAP2 and MHC-I proteins, which mediate increased tumor immune clearance. However, both cytokines also upregulate proteins such as PD-L1 (CD274) and IDO-1, which are associated with immune escape of cancer. Interestingly, differential expression of these genes was observed within the different cell lines and when comparing IL27 to IFN-. In coculture experiments of hepatocellular carcinoma (HCC) cells with peripheral blood mononuclear cells, pre-treatment of the HCC cells with IL27 resulted in lowered IL2 production by anti-CD3/-CD28 activated T-lymphocytes. Addition of anti-PD-L1 antibody, however, restored IL2 secretion. The levels of other T(H)1 cytokines were also enhanced or restored upon administration of anti-PD-L1. In addition, we show that the suppression of IL27 signaling by IL6-type cytokine pre-stimulationmimicking a situation occurring, for example, in IL6-secreting tumors or in tumor inflammation-induced cachexiacan be antagonized by antibodies against IL6-type cytokines or their receptors. Therapeutically, the antitumor effects of IL27 (mediated, e.g., by increased antigen presentation) might thus be increased by combining IL27 with blocking antibodies against PD-L1 or/and IL6-type cytokines.
Panic Disorder (PD) is characterized by unexpected, recurrent panic attacks, which are not restricted to certain situations, medication or stimuli. Like other anxiety disorders, PD is a multifactorial disorder and develops through the interaction of genetic and environmental risk factors. Despite an estimated heritability of up to 48%, no distinct genetic mechanism could be revealed yet. A dysregulation of the stress response has been shown in patients with PD and several studies could find an association of components of the corticotropin-releasing factor (CRF) system with PD. The corticotropin releasing hormone receptor 1 (CRHR1) is the main receptor of CRF in the brain and thus a crucial regulator of cerebral CRF signaling. Recent genetic studies found an association of certain CRHR1 single nucleotide polymorphisms (SNPs) with PD and other anxiety disorders. Among the associated CRHR1 SNPs, rs17689918 showed further evidence in a multilevel study regulating CRHR1 gene expression in panic-relevant brain regions and affecting brain activation in fMRI experiments, as well as flight behavior in a behavioral avoidance task (Weber et al, 2015). Here, we aimed to investigate the underlying neurogenetic and neurobiological mechanisms, by which the rs17689918 risk allele affects CRHR1 gene expression and receptor function, and its putative function in the pathophysiology of PD.
Due to its intronic position and the predicted change of splicing regulatory elements by the risk allele of rs17689918, the expression of alternative spliced CRHR1 isoforms was investigated using quantitative real-time PCR (qPCR) in a human post-mortem brain tissue sample. Of eight known CRHR1 isoforms, expression of three CRHR1 isoforms and the CRHR1-IT1-CRHR1 readthrough transcript variant 5 – all expressing the seven transmembrane domains needed for functional receptors – was analyzed. Subsequently, electrophysiological assays were developed to measure the receptor activity of differentially expressed CRHR1 isoforms via co-expressed Kir2.3 potassium channels in vitro. In a second approach, possible epigenetic regulation of CRHR1 expression by rs17689918 was investigated by analyses of DNA methylation patterns of a CpG Island within the CRHR1 promoter region, firstly in a case-control sample for PD and secondly in a healthy control sample, separated in high and low anxious individuals. To investigate a possible gene × epigene × environment interaction, the impact of early life stress by means of childhood trauma was evaluated via the childhood trauma questionnaire (CTQ). Finally, consequences of differential DNA methylation of the CRHR1 promoter region on gene expression were investigated by luciferase-based reporter gene assays in vitro.
The expression of CRHR1β was significantly decreased in amygdalae and midbrains of risk allele carriers. The expression of CRHR1-IT1-CRHR1 readthrough transcript variant 5 was significantly increased in forebrains and midbrains of risk allele carriers. All other analyzed isoforms showed no differences in expression between non-risk and risk allele carriers of rs17689918. The electrophysiological recordings of membrane potential showed an activation of Kir2.3 channels by CRHR1β in contrast to an inconsistent mix of activation and inhibition of Kir2.3 by the main isoform CRHR1α. DNA methylation of the CRHR1 promoter region was significantly reduced in panic disorder patients, as well as in high anxious individuals of an independent healthy control sample, but no direct relation to the rs17689918 risk allele could be discerned. However, the combination of carrying the risk allele, low DNA methylation and high CTQ scores lead to increased sum scores in the Beck Anxiety Inventory (BAI) in healthy individuals. Functional analyses revealed an activation of gene expression by decreased DNA methylation of the promoter region in vitro.
Our results revealed that rs17689918 regulates CRHR1 function by increasing the expression of alternative transcript variants with altered function. Our analyses of DNA methylation revealed decreased methylation as a new risk factor for panic disorder and high anxious behavior, which in combination with other risk factors like childhood trauma and the rs17689918 risk allele might further increase cognitive and somatic anxiety symptoms. This supports the role of CRHR1 as a plasticity gene of anxiety behavior, i.e. a gene that is highly regulated by epigenetic or post-transcriptional mechanisms in response to environmental stressors. By its role in CRF signaling, the dysregulation of CRHR1 might extensively affect the stress response and contribute to the pathophysiology of stress-related disorders like PD. The understanding of the underlying mechanisms, especially the genetic and epigenetic regulation, would however enhance CRHR1 as a target of improved future therapeutics for PD and other anxiety disorders.
Cardiovascular diseases represent the leading cause of death worldwide, with myocardial infarction and strokes being the most common complications. In both cases, the appearance of an enlarged artery wall as a consequence of a growing plaque is responsible for the disturbance of the blood flow. The formation of plaques is driven by a chronic inflammatory condition known as atherosclerosis, characterized by an initial step of endothelial cell (EC) dysfunction followed by the recruitment of circulating immune cells into the tunica intima of the vessel. Accumulation of lipids and cells lead to the formation of atheromatous plaques that will define the cardiovascular outcome of an individual.
The role of the immune system in the progression of atherosclerosis has been widely recognized. By far, macrophages constitute the most abundant cell type in lesions and are known to be the major source of the lipid-laden foam cell pool during the course of the disease. However, other immune cells types, including T cells, dendritic cells (DCs) or mast cells, among others, have been described to be present in human and mouse plaques. How these populations can modulate the atherogenic process is dependent on their specialized function.
DCs constitute a unique population with the ability to bridge innate and adaptive immune responses, mainly by their strong capacity to present antigens bound to a major histocompatibility complex (MHC) molecule. Given their ability to polarize T cells and secrete cytokines, their role in atherosclerosis has gained attention for the development of new therapeutic approaches that could impact lesion growth. Hence, knowing the effect of a specific subset is an initial key step to evaluate its potential for clinical purposes. For example, the basic leucine zipper ATF-like 3 transcription factor (Batf3) controls the development of conventional dendritic cells type 1 (cDCs1), characterized by the expression of the surface markers CD8 and CD103. Initially, they were described to promote both T-helper 1 (Th1) and regulatory T cell (Treg) responses, known to accelerate and to protect against atherosclerosis, respectively. The first part of this thesis aimed to elucidate the potential role of Batf3-dependent DCs in atherosclerosis and concluded that even though systemic immune responses were mildly altered they do not modify the course of the disease and may not represent an attractive candidate for clinical studies.
DCs also have the ability to impact lesion growth through the release of a broad range of cytokines, which can either directly impact atherosclerotic plaques by modulating resident cells, or by further polarizing T cell responses. Among others, interleukin (IL) 23, a member of the IL-12 family of cytokines, has received much attention during the past year due to its connection to autoimmunity.
IL-23 is known to induce pathogenicity of Th17 cells and is responsible for the development of several autoimmune diseases including multiple sclerosis, psoriasis or rheumatoid arthritis. Interestingly, these patients often present with an accelerated course of atherosclerosis and thus, are at higher risk of developing cardiovascular events. Several epidemiological studies have pointed toward a possible connection between IL-23 and its receptor IL-23R in atherosclerosis, although their exact contribution remains to be elucidated. The second part of this thesis showed that resident antigen-presenting cells (APCs) in the aorta produced IL-23 during the steady state but this secretion was greatly enhanced after incubation with oxidized low-density lipoprotein (oxLDL). Furthermore, disruption of the IL-23R signaling led to decreased relative necrotic plaque area in lesions of Ldlr-/-Il23r-/- mice fed a high-fat diet (HFD) for 6 and 12 weeks compared to Ldlr-/- controls. A proposed mechanism involves that increased IL-23 production in the context of atherosclerosis may promote the pathogenicity of IL-23-responding T cells, especially IL-23R+ γδ T cells in the aortic root. Response to IL-23 might increase the release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-17 and alter the pro- and anti-inflammatory balance of cytokines in the aortic root. Altogether, these data showed that the IL-23 / IL-23R axis play a role in plaque stability.
Abstract
Background: Attention-deficit/ hyperactivity disorder (ADHD) ranges among the most common neurodevelopmental disorders worldwide with a prevalence of 3-12% in childhood and 1-5% for adults. Over the last decade extensive genetic research has been conducted in order to determine its causative genetic factors. None of the so far identified susceptibility genes, however, could explain the estimated ADHD heritability of 76%. In this thesis one of the most promising candidates -Cadherin 13 (Cdh13) - was examined in terms of its influence on the central serotonergic (5-HT) system. In addition to that, the Cdh13 protein distribution pattern was analysed over time.
Methods: The developing serotonergic system was compared over three embryonic and postnatal stages (E13.5, E17.5 and P7) in different Cdh13 genotypes (WT, HZ and KO) using immunohistochemistry and various double staining protocols.
Results: The raphe nuclei of the 5-HT system develop in spite of Cdh13 absence and show a comparable mature constellation. The cells in the KO, however, are slightly more scattered than in the WT. Furthermore the dynamics of their formation is altered, with a transient delay in migration at E13.5. In early developmental stages the total amount of serotonergic cells is reduced in KO and HZ, though their proportional distribution to the raphe nuclei stays constant. Strikingly, at P7 the absolute numbers are comparable again.
Concerning the Cdh13 protein, it shows high concentrations on fibres running through hindbrain and midbrain areas at E13.5. This, however, changes over time, and it becomes more evenly spread until P7. Furthermore, its presence in serotonergic cells could be visualised using confocal microscopy. Since the described pattern is only in parts congruent to the localisation of serotonergic neurons, it is most likely that Cdh13 is present in other developing neurotransmitter systems, such as the dopaminergic one, as well.
Conclusion: It could be proven that Cdh13 is expressed in serotonergic cells and that its knockout does affect the developing serotonergic system to some degree. Its absence, however, only slightly and transiently affects the measured parameters of serotonergic system development, indicating a possible compensation of CDH13 function by other molecules in the case of Cdh13 deficiency. In addition further indicators could be found for an influence of Cdh13 on outgrowth and path finding of neuronal processes.
Melanoma and Merkel cell carcinoma (MCC) are highly aggressive cancers of the skin that frequently escape immune recognition and acquire resistance to chemotherapeutic agents, which poses a major obstacle to successful cancer treatment. Recently, a new class of therapeutics targeting the programmed cell death-1 (PD-1) immune checkpoint receptor has shown remarkable efficacy in the treatment of both cancers. Blockade of PD-1 on T cells activates cancer-specific immune responses that can mediate tumor regression. The data presented in this Ph.D. thesis demonstrates that PD-1 is also expressed by subsets of cancer cells in melanoma and MCC. Moreover, this work identifies PD-1 as a novel tumor cell-intrinsic growth receptor, even in the absence of T cell immunity. PD-1 is expressed by tumorigenic cell subsets in melanoma patient samples and established human and murine cell lines that also co-express ABCB5, a marker of immunoregulatory tumor- initiating cells in melanoma. Consistently, melanoma-expressed PD-1 downmodulates T effector cell functions and increases the intratumoral frequency of tolerogenic myeloid- derived suppressor cells. PD-1 inhibition on melanoma cells by RNA interference, blocking antibodies, or mutagenesis of melanoma-PD-1 signaling motifs suppresses tumor growth in immunocompetent, immunocompromised, and PD-1-deficient tumor graft recipient mice. Conversely, melanoma-specific PD-1 overexpression enhances tumorigenicity, including in mice lacking adaptive immunity. Engagement of melanoma- PD-1 by its ligand PD-L1 promotes tumor growth, whereas melanoma-PD-L1 inhibition or knockout of host-PD-L1 attenuates growth of PD-1-positive melanomas. Mechanistically, the melanoma-PD-1 receptor activates mTOR signaling mediators, including ribosomal protein S6. In a proof-of-concept study, tumoral expression of phospho-S6 in pretreatment tumor biopsies correlated with clinical responses to anti-PD-1 therapy in melanoma patients. In MCC, PD-1 is similarly co-expressed by ABCB5+ cancer cell subsets in clinical tumor specimens and established human cell lines. ABCB5 renders MCC cells resistant to the standard-of-care chemotherapeutic agents, carboplatin and etoposide. Antibody-mediated ABCB5 blockade reverses chemotherapy resistance and inhibits tumor xenograft growth by enhancing chemotherapy-induced tumor cell killing. Furthermore, engagement of MCC-expressed PD-1 by its ligands, PD-L1 and PD-L2, promotes proliferation and activates MCC-intrinsic mTOR signaling. Consistently, antibody- mediated PD-1 blockade inhibits MCC tumor xenograft growth and phosphorylation of mTOR effectors in immunocompromised mice. In summary, these findings identify cancer cell-intrinsic functions of the PD-1 pathway in tumorigenesis and suggest that blocking melanoma- and MCC-expressed PD-1 might contribute to the striking clinical efficacy of anti-PD-1 therapy. Additionally, these results establish ABCB5 as a previously unrecognized chemoresistance mechanism in MCC.
Previous work of our group has established a role of sphingomyelinases in the regulation
of T cell responses to TCR or pathogen stimulation, and this became particularly
evident at the level of actin cytoskeletal dynamics. The formation of lipid membrane
microdomains is crucial for receptor clustering and signal induction, and therefore,
ceramide accumulation by membrane sphingomyelin breakdown is needed for signalling-
complex-assembly. Pathogen-induced overshooting of SMase activation substantially
impacted the formation of membrane protrusions, with T cell spreading as well as
a front/rear polarisation upon CD3/CD28 co-stimulation [103]. On the other hand, NSM
activation is part of the physiological TCR signal [67], indicating that a spatiotemporally
balanced NSM activation is crucial for its physiological function. It involves actin cytoskeletal
reorganisation and T cell polarisation. These two functions are also of central
importance in directional T cell migration and motility in tissues.
This thesis aims on defining the role of NSM in compartmentalisation of the T cell
membrane in polarisation and migration. Therefore, functional studies on the impact of
NSM activity in these processes had to be complemented by the development of tools
to study ceramide compartmentalisation in living T cells.
The human-bacterial pathogen interaction is a complex process that results from
a prolonged evolutionary arms race in the struggle for survival. The pathogen employs
virulence strategies to achieve host colonization, and the latter counteracts using defense
programs. The encounter of both organisms results in drastic physiological changes
leading to stress, which is an ancient response accompanying infection. Recent evidence
suggests that the stress response in the host converges with the innate immune pathways
and influences the outcome of infection. However, the contribution of stress and the exact
mechanism(s) of its involvement in host defense remain to be elucidated. Using the model
bacterial pathogen Shigella flexneri, and comparing it with the closely related pathogen
Salmonella Typhimurium, this study investigated the role of host stress in the outcome of
infection.
Shigella infection is characterized by a pronounced pro-inflammatory response
that causes intense stress in host tissues, particularly the intestinal epithelium, which
constitutes the first barrier against Shigella colonization. In this study, inflammatory
stress was simulated in epithelial cells by inducing oxidative stress, hypoxia, and cytokine
stimulation. Shigella infection of epithelial cells exposed to such stresses was strongly
inhibited at the adhesion/binding stage. This resulted from the depletion of sphingolipidrafts
in the plasma membrane by the stress-activated sphingomyelinases. Interestingly,
Salmonella adhesion was not affected, by virtue of its flagellar motility, which allowed the
gathering of bacteria at remaining membrane rafts. Moreover, the intracellular replication
of Shigella lead to a similar sphingolipid-raft depletion in the membrane across adjacent
cells inhibiting extracellular bacterial invasion.
Additionally, this study shows that Shigella infection interferes with the host stress
granule-formation in response to stress. Interestingly, infected cells exhibited a nuclear
depletion of the global RNA-binding stress-granule associated proteins TIAR and TIA-1
and their accumulation in the cytoplasm.
Overall, this work investigated different aspects of the host stress-response in the
defense against bacterial infection. The findings shed light on the importance of the host
stress-pathways during infection, and improve the understanding of different strategies
in host-pathogen interaction.
The obligate intracellular pathogen Chlamydia trachomatis is the causative agent of
trachoma related blindness and the sexually transmitted pelvic inflammatory disease.
Being an obligate intracellular pathogen, C. trachomatis has an intricate dependency
on the survival of the host cell. This relationship is indispensible owing to the fact that
the pathogen spends a considerable fraction of its biphasic lifecycle within a
cytoplasmic vacuole inside the host cell, the so-called chlamydial inclusion. The
cellular apoptotic-signalling network is governed by several finely tuned regulatory
cascades composed of pro- and anti-apoptotic proteins that respond to changes in
the cellular homeostasis. In order to facilitate its intracellular survival, Chlamydia has
been known to inhibit the premature apoptosis of the host cell via the stabilization of
several host anti-apoptotic proteins such as cIAP2 and Mcl-1. While the pro- and
anti-apoptotic proteins are the major regulators of the host apoptotic signalling
network, a class of the small non-coding RNAs called microRNAs (miRNAs) has
increasingly gained focus as a new level of regulatory control over apoptosis.
This work investigates the changes in the host miRNA expression profile post
Chlamydia infection using a high throughput miRNA deep sequencing approach.
Several miRNAs previously associated with the modulation for apoptotic signalling
were differentially expressed upon Chlamydia infection in human endothelial cells. Of
the differentially regulated miRNAs, miR-30c-5p was of particular interest since it had
been previously shown to target the tumor suppressor protein p53. Our lab and
others have previously demonstrated that Chlamydia can downregulate the levels of
p53 by promoting its proteasomal degradation. This work demonstrates that
Chlamydia infection promotes p53 downregulation by increasing the abundance of
miR-30c-5p and a successful infection cycle is hindered by a loss of miR-30c-5p.
Over the last decade, dedicated research aimed towards a better understanding of
apoptotic stimuli has greatly improved our grasp on the subject. While extrinsic
stress, deprivation of survival signals and DNA damage are regarded as major
proponents of apoptotic induction, a significant responsibility lies with the
mitochondrial network of the cell. Mitochondrial function and dynamics are crucial to
cell fate determination and dysregulation of either is decisive for cell survival and
pathogenesis of several diseases. The ability of the mitochondrial network to perform
its essential tasks that include ATP synthesis, anti-oxidant defense, and calcium
homeostasis amongst numerous other processes critical to cellular equilibrium is tied
closely to the fission and fusion of individual mitochondrial fragments. It is, thus,
8
unsurprising that mitochondrial dynamics is closely linked to apoptosis. In fact, many
of the proteins involved regulation of mitochondrial dynamics are also involved in
apoptotic signalling. The mitochondrial fission regulator, Drp1 has previously been
shown to be transcriptionally regulated by p53 and is negatively affected by a miR-
30c mediated inhibition of p53. Our investigation reveals a significant alteration in the
mitochondrial dynamics of Chlamydia infected cells affected by the loss of Drp1. We
show that loss of Drp1 upon chlamydial infection is mediated by the miR-30c-5p
induced depletion of p53 and results in a hyper-fused architecture of the
mitochondrial network.
While it is widely accepted that Chlamydia depends on the host cell metabolism for
its intracellular growth and development, the role of mitochondria in an infected cell,
particularly with respect to its dynamic nature, has not been thoroughly investigated.
This work attempts to illustrate the dependence of Chlamydia on miR-30c-5p induced
changes in the mitochondrial architecture and highlight the importance of these
modulations for chlamydial growth and development.
Anxiety and depressive disorders result from a complex interplay of genetic and environmental factors and are common mutual comorbidities. On the level of cellular signaling, regulator of G protein signaling 2 (Rgs2) has been implicated in human and rodent anxiety as well as rodent depression. Rgs2 negatively regulates G protein-coupled receptor (GPCR) signaling by acting as a GTPase accelerating protein towards the Gα subunit.
The present study investigates, whether mice with a homozygous Rgs2 deletion (Rgs2-/-) show behavioral alterations as well as an increased susceptibility to stressful life events related to human anxiety and depressive disorders and tries to elucidate molecular underlying’s of these changes.
To this end, Rgs2-/- mice were characterized in an aversive-associative learning paradigm to evaluate learned fear as a model for the etiology of human anxiety disorders. Spatial learning and reward motivated spatial learning were evaluated to control for learning in non-aversive paradigms. Rgs2 deletion enhanced learning in all three paradigms, rendering increased learning upon deletion of Rgs2 not specific for aversive learning. These data support reports indicating increased long-term potentiation in Rgs2-/- mice and may predict treatment response to conditioning based behavior therapy in patients with polymorphisms associated with reduced RGS2 expression. Previous reports of increased innate anxiety were corroborated in three tests based on the approach-avoidance conflict. Interestingly, Rgs2-/- mice showed novelty-induced hypo-locomotion suggesting neophobia, which may translate to the clinical picture of agoraphobia in humans and reduced RGS2 expression in humans was associated with a higher incidence of panic disorder with agoraphobia. Depression-like behavior was more distinctive in female Rgs2-/- mice. Stress resilience, tested in an acute and a chronic stress paradigm, was also more distinctive in female Rgs2-/- mice, suggesting Rgs2 to contribute to sex specific effects of anxiety disorders and depression.
Rgs2 deletion was associated with GPCR expression changes of the adrenergic, serotonergic, dopaminergic and neuropeptide Y systems in the brain and heart as well as reduced monoaminergic neurotransmitter levels. Furthermore, the expression of two stress-related microRNAs was increased upon Rgs2 deletion. The aversive-associative learning paradigm induced a dynamic Rgs2 expression change. The observed molecular changes may contribute to the anxious and depressed phenotype as well as promote altered stress reactivity, while reflecting an alter basal stress level and a disrupted sympathetic tone. Dynamic Rgs2 expression may mediate changes in GPCR signaling duration during memory formation.
Taken together, Rgs2 deletion promotes increased anxiety-like and depression-like behavior, altered stress reactivity as well as increased cognitive function.